Cynosure Receives Approval to Market Cynergy(R) Workstation with MultiPlex(TM) Technology Laser System in Canada
June 01 2006 - 9:30AM
PR Newswire (US)
WESTFORD, Mass., June 1 /PRNewswire-FirstCall/ -- Cynosure, Inc.
(NASDAQ:CYNO), a leading developer and manufacturer of lasers and
pulsed light sources, today announced it has received Class III
medical device license approval from Health Canada to market and
sell its flagship Cynergy(R) workstation with MultiPlex(TM)
technology in Canada. "Canada represents an important market for
our products," said Michael R. Davin, CEO of Cynosure, Inc. "With
this Health Canada approval, physicians throughout the United
States and Canada can now use the Cynergy workstation with
MultiPlex technology for numerous conditions that were previously
deemed untreatable or difficult to treat, doing so with a greater
control of outcome, patient comfort and safety. "We believe the
Cynergy workstation with MultiPlex technology is the premier laser
technology for vascular applications, and an important
dermatological tool that addresses many cosmetic applications from
veins, birthmarks and pigmented lesions, to high volume services
such as hair removal and skin rejuvenation," Davin said. The
Cynergy workstation with MultiPlex technology is the first system
available that can sequentially emit with rapid succession, two
wavelengths from the same fiber optic -- a pulsed dye laser and an
Nd:YAG laser. The adjustable time delay between pulses increases
the safety and effectiveness of laser treatment. Cynosure plans to
market the Cynergy workstation with MultiPlex technology in Canada
through its direct sales force. "We believe international markets
can be key contributors in driving the adoption of our Cynergy
workstation with MultiPlex technology," Davin said. "Initial demand
in the United States has been strong, and we are looking to
continue this success in Canada." In a clinical study presented at
the American Society for Lasers in Medicine and Surgery in April
2006, by Dr. Emil Tanghetti, M.D., clinical professor of cosmetic
dermatology at the University of California, Davis, it was shown
that treatments utilizing the Cynergy workstation with MultiPlex
technology have an improved effectiveness in addressing facial and
leg telangiectasia when compared to treatments using a pulsed dye
laser or an Nd:YAG laser individually. This study demonstrated that
in 75 percent of the patients treated with this system, 70-80%
clearance was achieved for these types of lesions with a single
treatment. About Cynosure, Inc. Cynosure, Inc. develops and markets
aesthetic treatment systems that are used by physicians and other
practitioners to perform non-invasive procedures to remove hair,
treat vascular lesions, rejuvenate skin through the treatment of
shallow vascular and pigmented lesions and temporarily reduce the
appearance of cellulite. Cynosure's products include a broad range
of laser and other light-based energy sources, including
Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as
intense pulsed light. Cynosure was founded in 1991. For corporate
or product information, contact Cynosure at 800-886-2966, or visit
http://www.cynosurelaser.com/. Safe Harbor Any statements in this
press release about future expectations, plans and prospects for
Cynosure, Inc., including statements about the markets in which
Cynosure's products are sold and the use of and demand for the
Cynergy workstation with MultiPlex technology, and other statements
containing the words "believes," "anticipates," "plans," "expects,"
"will" and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important risk factors, including Cynosure's history of operating
losses, its reliance on sole source suppliers, competition in the
aesthetic laser industry, economic, market, technological and other
factors discussed in documents filed with the Securities and
Exchange Commission, including Cynosure's Annual Report on Form
10-K and Quarterly Report on Form 10-Q. The forward-looking
statements included in this press release represent Cynosure's
views as of the date of this press release. Cynosure anticipates
that subsequent events and developments will cause its views to
change. However, while Cynosure may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Cynosure's views as of any date subsequent to the date
of this press release. Contact: Timothy W. Baker 800-886-2966
DATASOURCE: Cynosure, Inc. CONTACT: Timothy W. Baker of Cynosure,
Inc., +1-800-886-2966, Web site: http://www.cynosurelaser.com/
Copyright
Cynosure (NASDAQ:CYNO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cynosure (NASDAQ:CYNO)
Historical Stock Chart
From Jul 2023 to Jul 2024